Home LATEST NEWS European Union clears Novavax’s COVID vaccine | Coronavirus

European Union clears Novavax’s COVID vaccine | Coronavirus


This is the fifth vaccine so approved in theEuropean Union, after those of Pfizer-BioNTech, Moderna, AstraZeneca and Johnson & Johnson.

Novavax’s vaccine uses a more traditional technology than the others, by using a protein base to trigger an immune response, without viruses. This could reduce the skepticism of some of the unvaccinated, reluctant to other technologies.

It is a welcome addition to the arsenal to protect Europeans. May it be a solid encouragement for the unvaccinated or those who have not been recalled! greeted Commission President Ursula von der Leyen in a statement.

The European Commission signed a contract with Novavax in August giving member states the option of purchasing up to 100 million doses of the Nuvaxovid vaccine for 2022, with an option of 100 million additional doses for 2022 and 2023.

Now that Brussels has granted the Novavax vaccine its conditional marketing authorization, the American laboratory will be able to start its deliveries in the next three months, with orders already confirmed for 27 million doses in theEuropean Union for the whole of the 1st quarter.

The Commission, which negotiates on behalf of the States, has in total ordered 2.4 billion doses of the vaccine from the American-German duo BioNTech / Pfizer, 460 million doses of the American Moderna, 400 million doses of the vaccine from the Swedish duo -British AstraZeneca and as much with the American Johnson & Johnson, according to a count published Monday by the European executive.

Vaccination and the administration of booster doses are even more important today if we want to stem the waves of contamination and counter the emergence of variants., as the rapid spread of the Omicron variant is raising concerns in Europe, said Health Commissioner Stella Kyriakides.

The Novavax vaccine is given as two injections, usually in the arm, three weeks apart.

The main clinical trials – one conducted in the UK and the other in the US and Mexico – involving more than 45,000 people have shown% “,” text “:” about 90% “}} ‘>about 90% effectiveness in reducing the number of symptomatic cases of COVID-19.

The side effects seen in the studies were generally mild or moderate and resolved within days of vaccination.

There are currently limited data on the efficacy of Nuvaxovid against other variants of concern, including Omicron. […] The safety and efficacy of the vaccine will continue to be monitored as it is used throughout the world.European Union.

A quote from The European Medicines Agency

The original strain of SARS-CoV-2 and some variants of concern such as Alpha and Beta were the most common viral strains circulating when studies were underway, she explained.

The serum, already authorized in Indonesia and the Philippines, can be stored at a temperature varying between 2 and 8 ° C – for example in a conventional refrigerator – which could facilitate its distribution, especially in less developed countries.

Previous articleOttawa and its allies denounce the conditions of the poll held in Hong Kong
Next articleDonald Trump files a complaint against the New York prosecutor to block an investigation